drugset / Trial / NCT06523504

Atropine (0.02%, 0.04%) Combined With Defocus DIMS for Moderate and High Myopia Control

NCT06523504

Phase 1/2 Recruiting 410 enrolled Ruihua Wei Beijing Tongren Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the effectiveness and safety of DIMS, low concentration atropine eye drops,and atropine combined with DIMS in controlling axial length and refraction in children with moderate to high myopia.

Timeline

Start
2024-02-01
Primary completion
2026-03-31
Completion
2026-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Atropine Other / unclassified 0.02 % Other
Subject Atropine Other / unclassified 0.04 % Other

Indications